Plain-English translation of NCT07850869 on ClinicalTrials.gov ↗ ·
This trial is testing a combination approach for advanced breast cancer that has stopped responding to standard treatments. H101, a specially designed virus, is injected directly into accessible tumors to trigger the cancer cells to die and alert the immune system. The virus is then combined with immune checkpoint inhibitor antibodies—medications that remove the 'brakes' on your immune system so it can better fight the cancer.
Many people with advanced breast cancer run out of effective treatment options after trying multiple standard therapies. This treatment aims to help by waking up the immune system in a new way—using a virus to directly attack tumors while simultaneously boosting immune cells that patrol the body for cancer.
You likely qualify if…
You likely don't qualify if…
You would receive treatment in 4 cycles, with each cycle lasting 2–3 weeks. During each cycle, doctors inject the medication directly into an accessible tumor on day 1, and then start the immune therapy infusion about a week later. Before treatment begins and after all 4 cycles are complete, you would undergo a repeat biopsy of the tumor and blood draws so researchers can study how your immune system changes. The study closely monitors you for side effects and tracks whether your tumors shrink.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China